The results of the 1,125-patient, randomized, double-blind ENZAMET trial are to be reported in a late-breaking abstract at the upcoming annual meeting of the American Society for Clinical Oncology (ASCO) in Chicago. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, ENZAMET, enzlutamide, hormone-sensitive, latitude, metastatic, mHSPC, outcome | 9 Comments »